Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment

Circulation Journal

Volumn 79, Issue 7, 2015, Pages 1486-1495

  Koretsune, Yukihiro ^a   Yamashita, Takeshi ^b   Kimura, Tetsuya ^c   Fukuzawa, Masayuki ^c   Abe, Kenji ^c   Yasaka, Masahiro ^d  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b THE CARDIOVASCULAR INSTITUTE   (Japan)

^c DAIICHI SANKYO CO   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Anticoagulants; Atrial fibrillation; Edoxaban; Renal impairment

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; EDOXABAN; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DRUG EFFECTS; FEMALE; FIBRINOLYSIS; HUMAN; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FACTOR XA INHIBITORS; FEMALE; FIBRINOLYSIS; HUMANS; JAPAN; MALE; MIDDLE AGED; PYRIDINES; RENAL INSUFFICIENCY, CHRONIC; THIAZOLES;

EID: 84934323965     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0942     Document Type: Article

References (23)

1. Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. Int J Cardiol 2009; 137: 102-107.
2. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009; 13: 621-630.
3. Tanaka H, Sonoda M, Kashima K, Tanaka Y, Nakamura K, Nuruki N, et al. Impact of decreased renal function on coagulation and fibrinolysis in patients with non-valvular atrial fibrillation. Circ J 2009; 73: 846-850.
4. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-1369.
5. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013) (in Japanese). http://www.j-circ.or.jp/ guideline/pdf/JCS2013_inoue_h.pdf (accessed May 8, 2014).
6. Prazaxa capsules (dabigatran etexilate) [package insert]. Tokyo: Boehringer Ingelheim, 2013 (in Japanese).
7. Xarelto tablets (rivaroxaban) [package insert]. Osaka: Bayer, 2012 (in Japanese).
8. Eliquis tablets (apixaban) [package insert]. Tokyo: Pfizer, 2013 (in Japanese).
9. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles. J Thromb Haemost 2008; 6: 1542-1549.
10. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 2012; 40: 2250-2255.
11. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012; 107: 925-936.
12. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
14. Ridout G, de la Motte S, Niemczyk S, Sramek P, Johnson L, Jin J, et al. Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PD model. J Clin Pharmacol 2009; 49: 1124 (abstract 1144).
15. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
16. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633-641.
17. Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamaguchi T, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 2012; 76: 1840-1847.
18. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
19. Lip GY, Frison L, Grind M; SPORTIF Investigators. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. J Intern Med 2008; 264: 50-61.
20. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743-753.
21. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87-92.
22. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010; 8: 2458-2468.
23. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. Am Heart J 2009; 158: 629-636.